(102) highlighted the need of deeper insight into the mechanisms on which the interaction between HR-positive/HER2-negative BC tumor and immune cells relies, as various factors such as menopausal status, estrogen levels, and endocrine treatments may be involved in the modulation of the tumor microenvironment (102). The gene discussed is ERBB2; the disease is breast cancer.